RxDoctor Payments Data

Timothy Price, MD

Internal Medicine · Washington, DCNPI 1942206792

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,150 of the $15,962 with a category attached, or 76.1%. 7 manufacturers reported payments, led by Gilead at 53.1% of the total. Reporting peaked in 2019 at $8,718 and has fallen 98.7% since, to $111 in 2025. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,962in general payments, 2019–2025

Across 59 payments — averaging $270.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$8K
  • Viiv Healthcare Company$7K
  • Janssen Products, LP$159
  • Theratechnologies Inc.$122
  • Novo Nordisk$40
  • Endo Pharmaceuticals Inc.$24
  • plus $18 from 1 others

What the payments were for

  • Consulting fees$12,15076%
  • Travel & lodging$2,02413%
  • Food & beverage$1,62810%
  • Education$1591%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,962 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$50,249
Medicare patients
93
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala55$288,346
OdefseyEmtricitab/Rilpiviri/Tenof Ala48$208,383
TivicayDolutegravir Sodium51$174,618
PrezcobixDarunavir/Cobicistat43$138,887
JulucaDolutegravir/Rilpivirine22$81,849
DescovyEmtricitabine/Tenofov Alafenam14$39,292
Etravirine13$14,685
Testosterone19$5,035
ValacyclovirValacyclovir Hcl25$1,079
Olmesartan Medoxomil50$1,038
Ezetimibe32$981
Rosuvastatin Calcium54$960
Atorvastatin Calcium74$645
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide17$567
Propranolol Hcl ErPropranolol Hcl13$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$8,480$327,63869 claims
Viiv Healthcare CompanyTivicay, Juluca$7,119$256,46873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →